| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447459 | European Journal of Cancer | 2011 | 8 Pages |
Abstract
Weekly docetaxel is less well tolerated than a 3-weekly schedule, due to more non-haematological toxicity, despite less febrile neutropenia. Also, no efficacy benefits can be demonstrated for weekly docetaxel, which may even be inferior based on multivariate analysis. Therefore, a 3-weekly schedule should be preferred in the setting of MBC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Carolien P. Schröder, Linda de Munck, Anneke M. Westermann, Willem M. Smit, Geert-Jan M. Creemers, Hiltje de Graaf, Jacqueline M. Stouthard, Gert van Deijk, Zoran Erjavec, Aart van Bochove, Willemijn Vader, Pax H. Willemse,